Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Circulation|November 3, 2025
Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic StrokeVictorien Monguillon, Peter Kelly, Michelle L O'Donoghue, et al.
European Heart Journal|November 28, 2009
Tissue Doppler E/E' ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudyAndrew S P Sharp, Robyn J Tapp, Simon A McG Thom, et al.
The New England Journal of Medicine|August 17, 2017
Cognitive Function in a Randomized Trial of EvolocumabRobert P Giugliano, François Mach, Kenton Zavitz, et al.
Circulation|November 12, 2019
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER TrialNicholas A Marston, Frederick K Kamanu, Francesco Nordio, et al.
JAMA Cardiology|June 14, 2018
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER TrialSeth S Martin, Robert P Giugliano, Sabina A Murphy, et al.
Circulation|November 15, 2017
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)Marc P Bonaca, Patrice Nault, Robert P Giugliano, et al.
Circulation|April 8, 2018
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIERMarc S Sabatine, Gaetano M De Ferrari, Robert P Giugliano, et al.
JAMA Cardiology|May 21, 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER TrialBaris Gencer, François Mach, Sabina A Murphy, et al.
Circulation|April 1, 2020
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous ThromboembolismNicholas A Marston, Yared Gurmu, Giorgio E M Melloni, et al.
JAMA Cardiology|April 30, 2020
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical TrialStephen D Wiviott, Robert P Giugliano, David A Morrow, et al.
Pageof 9